| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_c9839bac25346a8777263c0aac8b362b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b58f981963f6d55d627139e778c4ef7b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_841a2b66bdad24b0d9817d646c26ed17
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d08a26b0819347d0f8c884cc38722dcc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_1ef656abbba1eb6914a19718d6830811 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-25
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5154
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-35 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-2278
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0639 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-0784
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-22
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 |
| filingDate |
2000-07-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7e6db0e5182b5396a3ae599b0435d22d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_636ae75a95c8b76893db061d11b05e01
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_50a1f0d9c4d68a84ed7a4160de6963cd
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f26556f352a8b98162fe80003c1b6dae |
| publicationDate |
2001-01-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-0105423-A1 |
| titleOfInvention |
Use of vasoactive intestinal peptide (vip) for modulating the development of a specific immune response |
| abstract |
The invention concerns a novel effect of the vasoactive intestinal response (VIP) on its receptors showing that VIP and its antagonists exhibit novel therapeutic uses. It is shown that VIP induces maturation of dendritic cells and thereby promotes the development of a specific immune response. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2006064378-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2315081-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2315081-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2007104493-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2006064378-A3 |
| priorityDate |
1999-07-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |